Hologic

Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products dedicated to serve the healthcare needs of women. It operates through the following segments: Breast Health, Diagnostics, GYN Surgical, and Skeletal Health. The Breast Health segment includes a portfolio of solutions for breast cancer care for radiology, pathology, and surgery. The Diagnostics segment consists of products used to aid in the screening and diagnosis of human diseases. The GYN Surgical segment involves the NovaSure Endometrial Ablation System, the MyoSure Hysteroscopic Tissue Removal System, and the Fluent Fluid Management System. The Skeletal Health segment covers the Horizon DXA and the Fluoroscan Insight FD mini C-arm. The company was founded by S. David Ellenbogen and Jay A. Stein in 1985 and is headquartered in Marlborough, MA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Hologic exceeds Q1 earnings, eyes growth in women's health

Hologic's Q1 performance surpassed expectations, driven by strong organic growth and strategic initiatives. The company's commitment to women's health, financial strength, and focus on innovation position it well for future growth. Challenges in Breast Health highlight areas for improvement, while opportunities in new markets and products offer avenues for expansion.

Hologic surpasses Q2 expectations, eyes international growth and women's health

Hologic's Q2 performance exceeded expectations, driven by robust organic revenue growth and strong margins across divisions.
While facing challenges like COVID-related revenue declines and seasonal factors, the company's strategic strengths in women's health and international expansion present growth opportunities.
To sustain growth, Hologic must navigate macro uncertainties, balance growth drivers, and capitalize on opportunities in diagnostics and global expansion.
Overall, Hologic's solid financial results, increased revenue guidance, and strategic initiatives position the company for continued success in the healthcare market.

Hologic excels in Q3 earnings, eyes global growth amid challenges

Hologic delivered strong financial results in Q3 2023, driven by robust revenue growth and strategic product offerings across its divisions.
While facing margin challenges and geopolitical uncertainties, the company remains optimistic about sustaining growth and enhancing profitability through operational improvements.
With a focus on innovation, global expansion, and cautious M&A strategies, Hologic is well-positioned to capitalize on opportunities and navigate challenges in the healthcare market.

Hologic surpasses revenue targets, eyes international growth and strategic M&A

Hologic delivered strong financial performance in Q4 2023, exceeding revenue and EPS targets while emphasizing women's health and innovation.
The company's focus on international growth, strategic capital allocation, and product portfolio strength position it well for continued success.
Challenges in regulatory compliance, M&A decisions, and market dynamics require careful navigation for sustained growth.
Opportunities in international expansion, strategic M&A, and product innovation offer avenues for future growth and market leadership.

Hologic surpasses Q1 revenue expectations, eyes international growth opportunities

Hologic delivered strong Q1 2024 results, exceeding revenue guidance and showcasing robust financial performance with organic growth of 5.2% ex-COVID.
The company's focus on innovation, market expansion, and strong customer relationships positions it well for continued growth and success beyond COVID testing.
While facing challenges such as tough comps in Q2 and potential tax rate impacts, Hologic's disciplined growth strategies and commitment to transformative initiatives offer opportunities for future expansion.
With a strong emphasis on AI capabilities, market expansion, and strategic M&A, Hologic is poised for sustained growth and market leadership in the healthcare sector.

Hologic beats Q2 revenue targets, eyes international growth opportunities

Hologic exceeded revenue and EPS expectations in Q2 2024, showcasing growth in key business segments.
While facing challenges in certain revenue streams, the company is focused on international expansion and margin improvement.
Opportunities lie in leveraging international growth, strategic acquisitions, and product utilization trends.
Overall, Hologic's performance reflects resilience post-COVID and strategic focus on innovation and market positioning.

Hologic surpasses Q3 revenue expectations, eyes international growth opportunities

Hologic's Q3 performance reflects resilience and growth across key business segments, supported by strategic investments and operational excellence. With a focus on innovation and international expansion, the company is well-positioned for sustained growth and value creation in the evolving healthcare landscape.

Hologic exceeds Q4 earnings, eyes international growth and new products

Hologic's Q4 2024 earnings call showcased strong performance, strategic strengths, and growth opportunities. Challenges include maintaining margin expansion and balancing international growth. The company's focus on durable revenue base and new product pipeline sets a positive outlook for fiscal 2025.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products, that focuses on women’s health and well-being through early detection and treatment. It operates through the following segments: Breast Health, Diagnostics, GYN Surgical, and Skeletal Health. The Breast Health segment is involved in a portfolio of solutions for breast cancer care primarily in the areas of radiology, breast surgery, pathology and treatment. The Diagnostics segment offers a range of products, which are used primarily to aid in the screening and diagnosis of human diseases. The GYN Surgical segment is involved in hysteroscopic endometrial ablation systems, tissue removal systems, fluid management systems, and laparoscopic tissue ablation systems and tools. The Skeletal Health segment covers the Horizon DXA and the Fluoroscan Insight FD mini C-arm. The company was founded by S. David Ellenbogen and Jay A. Stein in 1985 and is headquartered in Marlborough, MA.

Align Technology

IDEXX Laboratories

Intuitive Surgical

Four large-cap MedTech stocks are currently flourishing on the back of several positive developments

4 Large Cap MedTech Stocks to Keep Winning Streaks Alive in 2021

Asbury Automotive Group

Norbord

Sprouts Farmers Markets

Top Ranked Growth Stocks to Buy for December 17th

ResMed

Thermo Fisher Scientific

West Pharmaceutical Services

Here are a few MedTech stocks which continued to outperform their respective industries amid the pandemic and can turn out to be wise investment choices.

5 MedTech Stocks That Have Outperformed the Industry in 2020

Does Hologic (HOLX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Here's Why Hologic (HOLX) is a Great Momentum Stock to Buy

Hologic (HOLX) could produce exceptional returns because of its solid growth attributes.

3 Reasons Why Growth Investors Shouldn't Overlook Hologic (HOLX)

General Motors

Owens & Minor

PerkinElmer

Top Ranked Growth Stocks to Buy for December 11th

Deere & Company

Qorvo

Wayfair

Williams-Sonoma

W, QRVO, WSM, DE, HOLX more than double the S&P 500's corresponding return in 2020.

5 Breakthrough Stocks Doubling S&P 500 Gains in 2020

Addus HomeCare

Fulgent Genetics

Here are a few MedTech growth stocks poised for a rebound that investors can scoop up to reap profits going into 2021.

3 MedTech Growth Stocks With Solid Prospects for 2021

Landbridge Co LLC

Micron Technology

Target

Here we pick four S&P 500 stocks -- LB, HOLX, MU & TGT -- that have strong growth prospects driven by the rising stimulus hopes and vaccine approvals.

S&P 500 Momentum to Continue on Stimulus Hopes: 4 Picks

QuidelOrtho Corp

Grab these four top stocks that have shown tremendous promise despite market volatility due to the pandemic and have the potential to continue their bull run in 2021.

4 Top-Ranked MedTech Stocks to Bet on Heading Into 2021

Avnet

Federated Hermes

Top Ranked Growth Stocks to Buy for December 8th

IPG Photonics

It will be prudent to invest in Zacks top-Ranked S&P 500 stocks that have skyrocketed year to date with strong potential for 2021. These include DE, HOLX, LB, PKI, IPGP, QRVO.

6 S&P 500 Must-Buy Stocks for 2021 Flying High Amid Pandemic

Hologic (HOLX) reported earnings 30 days ago. What's next for the stock?

Hologic (HOLX) Down 5.5% Since Last Earnings Report: Can It Rebound?

Hologic's (HOLX) latest 3D CAD solution is expected to aid in early detection of breast cancer along with prioritizing the most concerning patient cases.

Hologic's (HOLX) New AI Technology Now Available Post FDA Nod

Activision Blizzard

Brinker International

Five Below

Owens Corning

Invest in top-ranked stocks that are likely to beat their earnings estimates in the upcoming releases.

Looking for an Earnings Surprise? Play These 5 Stocks

Labcorp Holdings Inc

Here are a few coronavirus-testing MedTech stocks that investors can scoop up to reap profits amid the pandemic-battered stock market situation.

4 MedTech Stocks Gaining Ground on COVID-19 Test Kit Success

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #AI--Hologic Receives FDA Clearance for Latest Breakthrough in Early Breast Cancer Detection, Genius AI™ Detection

Hologic Receives FDA Clearance for Latest Breakthrough in Early Breast Cancer Detection, Genius AI™ Detection

TopBuild

Fair Isaac

After a detailed study of Driehaus' strategy, AAII concluded that it mainly focuses on strong earnings growth rates and impressive prospects to pick potential outperformers.

5 Best Momentum Picks Using Driehaus Strategy

Additional FDA approval for Hologic's (HOLX) molecular diagnostic test is expected to aid in the diagnosis of HIV infection.

Hologic (HOLX) Gets Additional FDA Nod, to Aid HIV Testing

MACOM Technology Solutions Holdings

Office Depot

Top Ranked Growth Stocks to Buy for November 25th

If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Hologic (HOLX).

Why Hologic (HOLX) Could Be an Impressive Growth Stock

Hologic (HOLX) becomes the provider of the first CE-Marked comprehensive cervical cancer screening portfolio with the new Genius Digital Diagnostics System.

Hologic's (HOLX) Cervical Cancer Screening System Gets CE Mark

Artisan Partners Asset Management

Top Ranked Growth Stocks to Buy for November 17th

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic Announces CE Mark of the Genius™ Digital Diagnostics System for Cervical Cancer Screening

Hologic Announces CE Mark of the Genius™ Digital Diagnostics System for Cervical Cancer Screening

NVIDIA

A Company to Watch in the Broader Technology Sector and One Making Big Inroads in Women's Health.

News for Hologic Stock (HOLX)